

Q1 cont 3); or direct equivalents thereof in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.--

Please replace the paragraph beginning at page 2, line 1, with the following rewritten paragraph;

Q2 --a) a first domain comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3) and, b) a second domain comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence Ser-Ala-Ser-Ser-Ser-Ile-Ser-Tyr-Met-Gln (SEQ ID NO:4), said CDR2' having the amino acid sequence Asp-Thr-Ser-Lys-Leu-Ala-Ser (SEQ ID NO: 5), and said CDR3' having the amino acid sequence His-Gln-Arg-Ser-Ser-Tyr-Thr (SEQ ID NO:6); or direct equivalents thereof.--

Please replace the paragraph beginning at page 3, line 1, with the following rewritten paragraph:

Q3 --the constant part or fragment thereof of a human heavy chain; said CDR1 having the amino acid sequence Arg-Tyr-Met-His (SEQ ID NO:1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3) and b) one immunoglobulin light chain or fragment thereof which comprises (i) a variable domain comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3' and (ii) the constant part or fragment thereof of a human light chain; said CDR1' having the amino acid sequence Ser-Ala-Ser-Ser-Ser-Ile-Ser-Tyr-Met-Gln (SEQ ID NO:4), said CDR2' having the amino acid sequence Asp-Thr-Ser-Lys-Leu-Ala-Ser (SEQ ID NO:5), and said CDR3' having the amino acid sequence His-Gln-Arg-Ser-Ser-Tyr-Thr (SEQ ID NO:6); and direct equivalents thereof.—

Please insert the paper copy of the attached Sequence Listing after page 10 and before the Claims and renumber the pages of the application.